REFERENCES

• LiebermanJA.TollefsonG.TohenM.et alComparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.Am J Psychiatry.200316081396140412900300
   PubMed Web of Science ®Google Scholar
• LiebermanJA.StroupTS.McEvoyJP.et alEffectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med.2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• BousmanCA.HopwoodM.Commercial pharmacogenetic-based decision-support tools in psychiatry.Lancet Psychiatry.20163658559027133546
   PubMed Web of Science ®Google Scholar
• SwenJJ.NijenhuisM.de BoerA.et alPharmacogenetics: from bench to byte— an update of guidelines.Clin Pharmacol Ther.201189566267321412232
   PubMed Web of Science ®Google Scholar
• Genetic Test Registry Bethesda, MD: National Center for Biotechnology Information, US National Library of Medicine. Available at: http:// www.ncbi.nlm.nih.gov/gtr/. Accessed February 19, 2016.
   Google Scholar
• ScottSA.SangkuhlK.SteinCM.et alClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Clin Pharmacol Ther.201394331732323698643
   PubMed Web of Science ®Google Scholar
• CacabelosR.HashimotoR.TakedaM.Pharmacogenomics of antipsychotics efficacy for schizophrenia.Psychiatry Clin Neurosci.201165131921265934
   PubMed Web of Science ®Google Scholar
• FDA Approved Drug Products. Rockville, MD: US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/. Accessed February 4, 2016.
   Google Scholar
• DahlML.LlerenaA.BondessonU.LindströmL.BertilssonL.Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.Br J Clin Pharmacol.199437171748148222
   PubMed Web of Science ®Google Scholar
• HäggS.SpigsetO.LaksoHA.DahlqvistR.Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.Eur J Clin Pharmacol.2001576-749349711699614
   PubMed Web of Science ®Google Scholar
• KimKA.JooHJ.LeeHM.ParkJY.Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers.Pharmacogenet Genomics.2014241354224240480
   PubMed Web of Science ®Google Scholar
• SunwooYE.RyuJ.JungH.et alDisposition of chlorpromazine in Korean healthy subjects with CYP2D6 wild type and *10B mutation.Clin Pharmacol Ther.2004752P90P90
   Web of Science ®Google Scholar
• Dahl-PuustinenML.LidenA.AimC.NordinC.BertilssonL.Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.Clin Pharmacol Ther.198946178812743709
   PubMed Web of Science ®Google Scholar
• OzdemirV.BertilssonL.MiuraJ.et alCYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.Pharmacogenet Genomics.200717533934717429316
   PubMed Web of Science ®Google Scholar
• DestaZ.KerbuschT.FlockhartDA.Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).Clin Pharmacol Ther.199965110209951426
   PubMed Web of Science ®Google Scholar
• vonBahr C.MovinG.NordinC.et alPlasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.Clin Pharmacol Ther.19914932342402007317
   PubMed Web of Science ®Google Scholar
• RavynD.RavynV.LowneyR.NasrallahHA.CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence.Schizophrfles. 20131491-3114
   Google Scholar
• OwenRP.SangkuhlK.KleinTE.AltmanRB.Cytochrome P450 2D6.Pharmacogenet Genomics.200919755956219512959
   PubMed Web of Science ®Google Scholar
• ZhouS-F.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clin Pharmacokinet.2009481168972319817501
   PubMed Web of Science ®Google Scholar
• Database of Single Nucleotide Polymorphisms (dbSNP) Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine. Available at: http://www.ncbi.nlm.nih.gov/projects/SNP/snp... ref.cgi showRare=on&chooseRs=coding&go=Go&locusld=18Q6. Accessed February 19, 2016.
   Google Scholar
• CascorbiI.Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication.Eur J Clin Invest.200333suppl 21722
   PubMed Web of Science ®Google Scholar
• SistonenJ.SajantilaA.LaoO.CoranderJ.BarbujaniG.FuselliS.CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.Pharmacogenet Genomics.20071729310117301689
   PubMed Web of Science ®Google Scholar
• AklilluE.PerssonI.BertilssonL.JohanssonI.RodriguesF.IngelmanSundbergM.Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.J Pharmacol Exp Ther.199627814414468764380
   PubMed Web of Science ®Google Scholar
• MullerDJ.BrandlEJ.HwangR.et alThe AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.Genet Test Mol Biomarkers.201216889790322775532
   PubMed Web of Science ®Google Scholar
• GrossmanI.SullivanPF.WalleyN.et alGenetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study.Genet Med.2008101072072918813134
   PubMed Web of Science ®Google Scholar
• FleemanN.DundarY.DicksonR.et alCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.Pharmacogenomics J.201111111420877299
   PubMed Web of Science ®Google Scholar
• BrockmöllerJ.KirchheinerJ.SchmiderJ.et alThe impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.Clin Pharmacol Ther.200272443845212386646
   PubMed Web of Science ®Google Scholar
• RasmussenBB.BrixTH.KyvikKO.BrosenK.The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors.Pharmacogenetics.200212647347812172216
   PubMedGoogle Scholar
• ThornCF.AklilluE.KleinTE.AltmanRB.PharmGKB summary: very important pharmacogene information for CYP1A2.Pharmacogenet Genomics.2012221737721989077
   PubMed Web of Science ®Google Scholar
• HartzSM.PatoCN.MedeirosH.et alComorbidity of severe psychotic disorders with measures of substance use.JAMA Psychiatry.2014713248254glycoprotein: implications for drug delivery and activity in cancer chemotherapy
   Web of Science ®Google Scholar
• DesaiHD.SeaboltJ.JannMW.Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.CNS Drugs.200115646949411524025
   PubMed Web of Science ®Google Scholar
• vander Weide J.SteijnsLS.vanWeelden MJ.The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement.Pharmacogenetics.200313316917212618594
   PubMedGoogle Scholar
• JaquenoudSirot E.KnezevicB.MorenaGP.et alABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.J Clin Psychopharmacol.200929431932619593168
   PubMed Web of Science ®Google Scholar
• OzdemirV.KalowW.OkeyAB.et alTreatment-resistance to clozapine in association with ultrarapid CYP1 A2 activity and the C— >A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and lowdose fluvoxamine.J Clin Psychopharmacol.200121660360711763009
   PubMed Web of Science ®Google Scholar
• EapCB.BenderS.JaquenoudSirot E.et alNonresponse to clozapine and ultrarapid CYP1 A2 activity: clinical data and analysis of CYP1 A2 gene.J Clin Psychopharmacol.200424221421915206669
   PubMed Web of Science ®Google Scholar
• PereraV.GrossAS.PolasekTM.et alConsidering CYP1 A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Expert Opin Drug Metab Toxicol.2013991115113723641727
   PubMed Web of Science ®Google Scholar
• NozawaM.OhnumaT.MatsubaraY.et alThe relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).Ther Drug Monit.2008301354018223460
   PubMed Web of Science ®Google Scholar
• CzerwenskyF.LeuchtS.SteimerW.CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Ther Drug Monit.201537215216025090458
   PubMed Web of Science ®Google Scholar
• ZangerUM.TurpeinenM.KleinK.SchwabM.Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Anal BioanalChem.2008392610931108
   Google Scholar
• Whirl-CarrilloM.McDonaghEM.HebertJM.et alPharmacogenomics knowledge for personalized medicine.Clin Pharmacol Ther.201292441441722992668
   PubMed Web of Science ®Google Scholar
• CYP3A4 allele nomenclature. Stockholm, Sweden: The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http:// www.cypalleles.ki.se/cyp3a4.htm. Accessed February 19, 2016.
   Google Scholar
• LambaJ.HebertJM.SchuetzEG.KleinTE.AltmanRB.PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenet Genomics.201222755555822407409
   PubMed Web of Science ®Google Scholar
• BigosKL.BiesRR.PollockBG.LowyJJ.ZhangF.WeinbergerDR.Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Mol Psychiatry.201116662062521519338
   PubMed Web of Science ®Google Scholar
• BakkenGV.MoldenE.HermannM.Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients.Ther Drug Monit.201537225626125254417
   PubMed Web of Science ®Google Scholar
• SoderbergMM.MoldenE.DahlML.No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Pharmacogenet Genomics.201424527227524595013
   PubMed Web of Science ®Google Scholar
• ThiebautF.TsuruoT.HamadaH.GottesmanMM.PastanI.WillinghamMC.Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proc Natl Acad Sci U S A.19878421773577382444983
   PubMed Web of Science ®Google Scholar
• EichelbaumM.FrommMF.SchwabM.Clinical aspects of the MDR1 (ABCB1) gene polymorphism.Ther Drug Monit.200426218018515228162
   PubMed Web of Science ®Google Scholar
• MoonsT.deRoo M.ClaesS.DomG.Relationship between P-glycoprotein and second-generation antipsychotics.Pharmacogenomics.20111281193121121843066
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyC.OhJM.KimIW.et alA “silent” polymorphism in the MDR1 gene changes substrate specificity.Science2007315581152552817185560
   PubMed Web of Science ®Google Scholar
• FungKL.PanJ.OhnumaS.et alMDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.Cancer Res.201474259860824305879
   PubMed Web of Science ®Google Scholar
• WacherVJ.WuCY.Benet alLZ.Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.Moi Carcinog.19951331291347619215
   PubMed Web of Science ®Google Scholar
• ZhangJP.MalhotraAK.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Expert Opin Drug Metab Toxicol.20117193721162693
   PubMed Web of Science ®Google Scholar
• Pouget alJG.MullerDJ.Pharmacogenetics of antipsychotic treatment in schizophrenia.Methods Mol Biol.2014117555758725150876
   PubMedGoogle Scholar
• HuangE.ZaiCC.LisowayA.et alCatechol-O-methyltransferase Val1 58Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. 2016 Apr 29. Epub ahead of print. doi:10.1093/ijnp/ pyv132Int J Neuropsychopharmacol.
   Google Scholar
• BakkerPR.vanHarten PN.vanOs J.Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.Mol Psychiatry.200813554455618180754
   PubMed Web of Science ®Google Scholar
• ZaiCC.De LucaV.HwangRW.et alMeta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.Mol Psychiatry.200712979479517767146
   PubMed Web of Science ®Google Scholar
• ZhangJP.LenczT.MalhotraAK.D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.Am J Psychiatry.2010167776377220194480
   PubMed Web of Science ®Google Scholar
• TsaiH-T.NorthKE.WestSL.PooleC.The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis.Am J Med Genet B Neuropsychiatr Genet.2010153B1576619358223
   PubMed Web of Science ®Google Scholar
• LererB.SegmanRH.TanEC.et alCombined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.Int J Neuropsychopharmacol.20058341142515857569
   PubMed Web of Science ®Google Scholar
• ZhangJP.MalhotraAK.Pharmacogenetics of antipsychotics: recent progress and methodological issues.Expert Opin Drug Metab Toxicol.20139218319123199282
   PubMed Web of Science ®Google Scholar
• MissaleC.NashSR.RobinsonSW.JaberM.CaronMG.Dopamine receptors: from structure to function.Physiol Rev.19987811892259457173
   PubMed Web of Science ®Google Scholar
• PanYQ.QiaoL.XueXD.FuJH.Association between ANKK1 (rs1800497) polymorphism of DRD2 gene and attention deficit hyperactivity disorder: a meta-analysis. Neurosci Lett201559010110525641135
   PubMed Web of Science ®Google Scholar
• YuanA.SuL.YuS.LiC.YuT.SunJ.Association between DRD2/ANKKI TaqlA polymorphism and susceptibility with Tourette syndrome: a meta-analysis. PLoS One2015106e0131060
   Web of Science ®Google Scholar
• YaoJ.PanYQ.DingM.PangH.WangBJ.Association between >DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis.Am J Med Genet B Neuropsychiatr Genet.2015168B111325504812
   PubMedGoogle Scholar
• WangF.SimenA.AriasA.LuQW.ZhangH.A large-scale meta-analysis of the association between the ANKKI/DRD2 TaqlA polymorphism and alcohol dependence.Hum Genet.2013132334735823203481
   PubMed Web of Science ®Google Scholar
• ThompsonJ.ThomasN.SingletonA.et alD2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.Pharmacogenetics.1997764794849429233
   PubMedGoogle Scholar
• PohjalainenT.RinneJO.NägrenK.et alThe A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.Mol Psychiatry.1998332562609672901
   PubMed Web of Science ®Google Scholar
• JönssonEG.NöthenMM.GrunhageF.et alPolymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.Mol Psychiatry.19994329029610395223
   PubMed Web of Science ®Google Scholar
• ZhangY.BertolinoA.FazioL.et alPolymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.Proc Natl Acad Sci U S A.200710451205522055718077373
   PubMed Web of Science ®Google Scholar
• MullerDJ.ZaiCC.SicardM.et alSystematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J201212215616420714340
   PubMed Web of Science ®Google Scholar
• CalargeCA.EllingrodVL.AcionL.et alVariants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Pharmacogenet Genomics.200919537338219339912
   PubMed Web of Science ®Google Scholar
• YoungRM.LawfordBR.BarnesM.et alProlactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2 *A1 allele.Br J Psychiatry.200418514715115286066
   PubMed Web of Science ®Google Scholar
• ArinamiT.GaoM.HamaguchiH.ToruM.A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia.Hum Mol Genet.1997645775829097961
   PubMed Web of Science ®Google Scholar
• SuzukiA.KondoT.MiharaK.et alThe -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.Pharmacogenetics.200111654555011505224
   PubMedGoogle Scholar
• YamanouchiY.IwataN.SuzukiT.KitajimaT.IkedaM.OzakiN.Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.Pharmacogenomics J.20033635636114610521
   PubMed Web of Science ®Google Scholar
• LenczT.RobinsonDG.XuK.et alDRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in firstepisode schizophreniapatients. Am J Psychiatry.2006163352953116513877
   PubMed Web of Science ®Google Scholar
• JoyceJN.GurevichEV.D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics.Ann N Y Acad Sci.199987759561310415673
   PubMed Web of Science ®Google Scholar
• SchwartzJC.DiazJ.PilonC.SokoloffP.Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions.Brain Res Brain Res Rev.2000312-327728710719154
   PubMedGoogle Scholar
• SokoloffP.DiazJ.LeFoil B.et alThe dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.CNS Neurol Disord Drug Targets.200651254316613552
   PubMedGoogle Scholar
• HwangR.ZaiC.TiwariA.et alEffect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant.Pharmacogenomics J.201010320021820029384
   PubMed Web of Science ®Google Scholar
• BakkerPR.vanHarten PN.vanOs J.Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.Schizophr Res.2006832-318519216513329
   PubMed Web of Science ®Google Scholar
• LererB.SegmanRH.FangerauH.et alPharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.Neuropsychopharmacology.200227110511912062911
   PubMed Web of Science ®Google Scholar
• ChenJ.LipskaBK.HalimN.et alFunctional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet.200475580782115457404
   PubMed Web of Science ®Google Scholar
• BertolinoA.CaforioG.BlasiG.et alInteraction of COMT Val108/158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.Am J Psychiatry.2004161101798180515465976
   PubMed Web of Science ®Google Scholar
• BertolinoA.CaforioG.BlasiG.et alCOMT Val1 58Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.Schizophr Res.2007951325325517644310
   PubMed Web of Science ®Google Scholar
• MoleroP.OrtuñoF.ZalacainM.Patiño-GarcíaA.Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.Pharmacogenomics J.20077641842617363961
   PubMed Web of Science ®Google Scholar
• WoodwardND.JayathilakeK.MeltzerHY.COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.Schizophr Res.20079013869617123785
   PubMed Web of Science ®Google Scholar
• Pelayo-TeránJM.Pérez-IglesiasR.Vazquez-BourgonJ.et alCatechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis.Psychiatry Res.20111851-228628920591499
   PubMed Web of Science ®Google Scholar
• WeickertTW.GoldbergTE.MisharaA.et alCatechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications.Biol Psychiatry.200456967768215522252
   PubMed Web of Science ®Google Scholar
• ChenH.TuJ.NiP.ZhangW.XuL.COMT genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis [in Chinese],Zhong Nan Da Xue Xue Bao YiXue Ban.2015406623631
   PubMedGoogle Scholar
• LvZRongB.TongX.etalThe association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk. Int J Neurosci.201517
   Web of Science ®Google Scholar
• MeltzerHY.MasseyBW.HoriguchiM.Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.Curr Pharm Biotechnol.20121381572158622283753
   PubMed Web of Science ®Google Scholar
• MeltzerHY.The mechanism of action of novel antipsychotic drugs.Schizophr Bull.19911722632871679253
   PubMed Web of Science ®Google Scholar
• ArranzMJ.MunroJ.ShamP.et alMeta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.Schizophr Res.199832293999713904
   PubMed Web of Science ®Google Scholar
• Polesskaya00.AstonC.SokolovBP.Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylaseDNMT1. J Neurosci Res.200683336237316358338
   PubMed Web of Science ®Google Scholar
• ParsonsMJ.D'SouzaUM.ArranzMJ.KerwinRW.MakoffAJ.The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity.Biol Psychiatry.200456640641015364038
   PubMed Web of Science ®Google Scholar
• MyersRL.AireyDC.ManierDH.SheltonRC.Sanders-BushE.Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression.Biol Psychiatry.200761216717316697352
   PubMed Web of Science ®Google Scholar
• Blanc0.BrousseG.MearyA.LeboyerM.LlorcaPM.Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research.Fundam Clin Pharmacol.201024213916019702693
   PubMed Web of Science ®Google Scholar
• ArranzMJ.CollierDA.MunroJ.et alAnalysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.NeurosciLett.19962172-3177178
   PubMed Web of Science ®Google Scholar
• HazelwoodLA.Sanders-BushE.His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation.Mol Pharmacol.20046651293130015496511
   PubMed Web of Science ®Google Scholar
• MasellisM.BasileV.MeltzerHY.et alSerotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.Neuropsychopharmacology.19981921231329629566
   PubMed Web of Science ®Google Scholar
• ArranzMJ.MunroJ.OwenMJ.et alEvidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.Mol Psychiatry.19983161669491814
   PubMed Web of Science ®Google Scholar
• aikaB.LeuchtS.HeresS.SchneiderH.SteimerW.Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Pharmacogenomics J.2010101202919636338
   PubMed Web of Science ®Google Scholar
• TangH.McGowan00.ReynoldsGP.Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action.Pharmacogenomics.201415121599160925340734
   PubMed Web of Science ®Google Scholar
• ReynoldsGP.KirkSL.Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms.Pharmacol Ther.2010125116917919931306
   PubMed Web of Science ®Google Scholar
• Veenstra-VanderWeeleJ.AndersonGM.CookEH Jr.Pharmacogenetics and the serotonin system: initial studies and future directions.Eur J Pharmacol.20004102-316518111134668
   PubMed Web of Science ®Google Scholar
• SicardMN.ZaiCC.TiwariAK.et alPolymorphisms of the HTR2Cgene and antipsychotic-induced weight gain: an update and meta-analysis.Pharmacogenomics.201011111561157121121776
   PubMed Web of Science ®Google Scholar
• WallaceTJ.ZaiCC.BrandlEJ.MullerDJ.Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain.Pharmgenomics Pers Med.20114839323226055
   PubMedGoogle Scholar
• HillMJ.ReynoldsGP.Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain.Pharmacogenomics.201112572773421391883
   PubMed Web of Science ®Google Scholar
• TecottLH.SunLM.AkanaSF.et alEating disorder and epilepsy in mice lacking 5-HT2Cserotonin receptors.Nature.199537465225425467700379
   PubMed Web of Science ®Google Scholar
• RellingMV.EvansWE.Pharmacogenomics in the clinic.Nature.2015526757334335026469045
   PubMed Web of Science ®Google Scholar